ATE343577T1 - Quinolinone als prostaglandin rezeptor liganden - Google Patents

Quinolinone als prostaglandin rezeptor liganden

Info

Publication number: ATE343577T1
Authority: AT; Austria
Prior art keywords: quinolinone; receptor ligands; prostaglandin receptor; prostaglandin; condition
Prior art date: 2001-12-14

Application number

AT02784961T

Other languages

English (en)

Inventor

Daniel Dube

Denis Deschenes

Rejean Fortin

Yves Girard

Original Assignee

Merck Frosst Canada Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-14

Filing date

2002-12-11

Publication date

2006-11-15

2002-12-11 Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd

2006-11-15 Application granted granted Critical

2006-11-15 Publication of ATE343577T1 publication Critical patent/ATE343577T1/de

Links

102000015433 Prostaglandin Receptors Human genes 0.000 title 1
108010050183 Prostaglandin Receptors Proteins 0.000 title 1
239000003446 ligand Substances 0.000 title 1
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title 1
229930185107 quinolinone Natural products 0.000 title 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
230000001404 mediated effect Effects 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)

AT02784961T 2001-12-14 2002-12-11 Quinolinone als prostaglandin rezeptor liganden ATE343577T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US34043901P	2001-12-14	2001-12-14

Publications (1)

Publication Number	Publication Date
ATE343577T1 true ATE343577T1 (de)	2006-11-15

Family

ID=23333355

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02784961T ATE343577T1 (de)	2001-12-14	2002-12-11	Quinolinone als prostaglandin rezeptor liganden

Country Status (9)

Country	Link
US (1)	US7348433B2 (de)
EP (1)	EP1458718B1 (de)
JP (1)	JP2005520797A (de)
AT (1)	ATE343577T1 (de)
AU (1)	AU2002350315B2 (de)
CA (1)	CA2469048A1 (de)
DE (1)	DE60215699T2 (de)
ES (1)	ES2274111T3 (de)
WO (1)	WO2003051878A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE533766T1 (de)	2005-05-19	2011-12-15	Merck Canada Inc	Chinolinderivate als ep4-antagonisten
WO2007008125A1 (en)	2005-07-13	2007-01-18	Sca Hygiene Products Ab	Absorbent article having improved fit
JP4954997B2 (ja)	2005-07-13	2012-06-20	エスセーアー・ハイジーン・プロダクツ・アーベー	適合性が改善された吸収用品
GB2439719A (en)	2006-07-05	2008-01-09	Sca Hygiene Prod Ab	Absorbent article with differing core density regions
US9603848B2 (en)	2007-06-08	2017-03-28	Senomyx, Inc.	Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) *	2007-06-08	2011-04-19	Senomyx, Inc.	Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
EP2201374B1 (de) *	2007-08-30	2015-10-07	Trustees Of Tufts College	Verfahren zur bestimmung der konzentration eines analyten in lösung
EP3085699B1 (de)	2008-07-31	2022-03-02	Firmenich Incorporated	Verfahren zur herstellung von verstärkern des süssen geschmacks
JP2015178457A (ja) *	2012-07-25	2015-10-08	杏林製薬株式会社	ピラゾロピリジン誘導体、またはその薬理学的に許容される塩
AU2013299859B2 (en)	2012-08-06	2017-06-15	Firmenich Incorporated	Sweet flavor modifier
JO3155B1 (ar)	2013-02-19	2017-09-20	Senomyx Inc	معدِّل نكهة حلوة
CN103319403B (zh) *	2013-05-10	2016-03-30	重庆理工大学	一种肿瘤血管新生抑制剂己啉酮及其制备方法和用途
CA3042642A1 (en)	2013-08-12	2015-02-19	Pharmaceutical Manufacturing Research Services, Inc.	Extruded immediate release abuse deterrent pill
KR101731102B1 (ko)	2013-10-01	2017-04-27	광주과학기술원	신규한 퀴놀리논 유도체 및 이의 용도
CN103664777A (zh) *	2013-10-09	2014-03-26	重庆理工大学	一种美啉醇化合物、制备方法及其药物组合物和用途
WO2015095391A1 (en)	2013-12-17	2015-06-25	Pharmaceutical Manufacturing Research Services, Inc.	Extruded extended release abuse deterrent pill
US9492444B2 (en)	2013-12-17	2016-11-15	Pharmaceutical Manufacturing Research Services, Inc.	Extruded extended release abuse deterrent pill
CN103755697B (zh) *	2014-01-14	2015-08-05	湖南大学	3-[[2-(2-苄亚氨基)噻唑-5-基]甲基]喹啉-2(1h)-酮及其制备与应用
CN103739599B (zh) *	2014-01-15	2015-10-07	湖南大学	3-[[2-(2-苄亚肼基)噻唑-5-基]甲基]喹啉-2(1h)-酮及其制备与应用
DK3169315T3 (da)	2014-07-17	2020-08-10	Pharmaceutical Manufacturing Res Services In	Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
AU2015336065A1 (en)	2014-10-20	2017-05-04	Pharmaceutical Manufacturing Research Services, Inc.	Extended release abuse deterrent liquid fill dosage form
CN104628717B (zh) *	2015-03-16	2017-02-15	湖南大学	3‑[5‑(1，2，4‑三唑‑1‑基)噻唑‑2‑基]苯并噁嗪及其应用
CN105753857B (zh) *	2016-02-16	2018-05-22	湖南大学	苄亚氨基噻唑甲基喹啉酮衍生物的医药用途
CN105541827B (zh) *	2016-02-16	2018-01-19	湖南大学	苄亚肼基噻唑基甲基喹啉酮衍生物及其作为抗癌药的应用
CN105777739B (zh) *	2016-02-23	2018-05-08	湖南大学	萘氨基噻唑甲基喹啉酮衍生物及其医药用途
WO2020033420A1 (en)	2018-08-07	2020-02-13	Firmenich Incorporated	5-substituted 4-amino-1h-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof
US20240287022A1 (en) *	2021-06-28	2024-08-29	Merck Sharp & Dohme Llc	Il4i1 inhibitors and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5378694A (en) *	1990-09-07	1995-01-03	Schering Corporation	Acyl and alkoxy substituted quinolines
AU8665991A (en)	1990-09-07	1992-03-30	Schering Corporation	Antiviral compounds and antihypertensive compounds
DE19613591A1 (de) *	1996-04-04	1997-10-09	Hoechst Ag	Substituierte-Chinolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US6265421B1 (en) *	1997-06-25	2001-07-24	Orion Corporation	Phospholamban inhibitors and a method for increasing coronary flow
JP2002531549A (ja) *	1998-12-04	2002-09-24	ブリストル−マイヤーズスクイブカンパニー	カリウムチャネル・モジュレーターとしての３−置換−４−アリールキノリン−２−オン誘導体

2002
- 2002-12-11 CA CA002469048A patent/CA2469048A1/en not_active Abandoned
- 2002-12-11 DE DE60215699T patent/DE60215699T2/de not_active Expired - Fee Related
- 2002-12-11 AU AU2002350315A patent/AU2002350315B2/en not_active Ceased
- 2002-12-11 JP JP2003552762A patent/JP2005520797A/ja active Pending
- 2002-12-11 AT AT02784961T patent/ATE343577T1/de not_active IP Right Cessation
- 2002-12-11 ES ES02784961T patent/ES2274111T3/es not_active Expired - Lifetime
- 2002-12-11 EP EP02784961A patent/EP1458718B1/de not_active Expired - Lifetime
- 2002-12-11 US US10/498,084 patent/US7348433B2/en not_active Expired - Fee Related
- 2002-12-11 WO PCT/CA2002/001914 patent/WO2003051878A1/en not_active Ceased

Also Published As

Publication number	Publication date
CA2469048A1 (en)	2003-06-26
WO2003051878A1 (en)	2003-06-26
DE60215699T2 (de)	2007-08-30
US7348433B2 (en)	2008-03-25
AU2002350315A1 (en)	2003-06-30
EP1458718B1 (de)	2006-10-25
US20050222194A1 (en)	2005-10-06
ES2274111T3 (es)	2007-05-16
JP2005520797A (ja)	2005-07-14
AU2002350315B2 (en)	2008-05-22
DE60215699D1 (de)	2006-12-07
EP1458718A1 (de)	2004-09-22

Legal Events

Date	Code	Title	Description
2007-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60215699D1 (de)	2006-12-07	Quinolinone als prostaglandin rezeptor liganden
DE69529690D1 (de)	2003-03-27	Diaryl-2(5h)-fuaranone als cox-2-inhibitoren
WO2001081312A3 (en)	2002-08-08	Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
ATE189218T1 (de)	2000-02-15	Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren
DE60124085D1 (de)	2006-12-07	Pde-v hemmer zur behandlung von morbus parkinson
ES2168471T3 (es)	2002-06-16	2-(5h)-furanonas diaril-5-oxigenadas como inhibidores de la cox-2.
EA200201247A1 (ru)	2003-10-30	Соединения для лечения болезни альцгеймера
EA199900137A1 (ru)	1999-06-24	Замещенные пиридины в качестве избирательных ингибиторов циклооксигеназы-2
CY1109242T1 (el)	2014-07-02	Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
RU2010144637A (ru)	2012-05-27	Замещенные гамма-лактамы в качестве терапевтических агентов
DE69825154D1 (de)	2004-08-26	Pyridazinone als inhibitoren von cyclooxygenase-2
DE69825603D1 (de)	2004-09-16	2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2
EP1689713A4 (de)	2009-02-18	Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE399011T1 (de)	2008-07-15	Substituierte diketopiperazine als oxytocin- antagonisten
YU75803A (sh)	2006-05-25	Nova dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
DE60220385D1 (de)	2007-07-12	Benzimidazole zur behandlung sexueller fehlfunktionen
EA200101212A1 (ru)	2002-06-27	Замещенные полициклические арил- и гетероарилпиразиноны, которые могут использоваться при селективном ингибировании системы свертывания крови
ATE520691T1 (de)	2011-09-15	Shp-2-hemmer, pharmazeutische zusammensetzung damit und ihre verwendung zur behandlung phosphatase-vermittelter erkrankungen
ATE415965T1 (de)	2008-12-15	Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
ATE346040T1 (de)	2006-12-15	Aryl-sulfonamide als serotonin-antagonisten für de behandlung von fettleibigkeit
DE69829861D1 (de)	2005-05-25	2-aminopyridine als inhibitoren von cyclooxygenase-2
ATE315387T1 (de)	2006-02-15	Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
DE59609219D1 (de)	2002-06-20	Verwendung von 1-hydroxy-2-pyridonen zur behandlung von schwer therapierbaren schleimhauterkrankungen
ATE511395T1 (de)	2011-06-15	Mittel zur behandlung von glomerulopathie
ATE449607T1 (de)	2009-12-15	Arsentherapie zur behandlung von autoimmunerkrankungen